Anesthesia Pharmacology:  Physics and Anesthesiology

Anesthetic Circuitry

 

Section Table of Contents

Site Table of Contents

Previous Page

Next Page

  • 23Compound A, a metabolite of sevoflurane (Sevorane, Ultane), has been suggested to be a renal toxin.

  • Endpoints of renal toxicity might include abnormal albumin excretion, urinary glucose, and alpha-glutathione-S-transferase. 

    • Using these endpoints, compound A at doses < 240 ppm/hour did not induce abnormal levels of the aforementionned compounds.  By contrast, patients receiving doses > 240 ppm/hour exhibited increased, abnormal excretion of urinary albumin, glucose, and glutathione-S-transferase. 

    • In terms of relating these results to sevoflurane (Sevorane, Ultane) administration, Compound A levels exceeding 240 ppm//hour might be expected following prolonged sevoflurane (Sevorane, Ultane) anesthesia, for example eight hours at 2L/min flowrate. 

    • This administration corresponds to about 30 ppm Compound A exposure .which would then be expected or could produce a transient albuminuria and enzymuria in otherwise healthy patients

 

Dessicated Absorbents will degrade these Anesthetics

Enflurane (Ethrane)

Desflurane (Suprane)

Isoflurane (Forane)

 

Section Table of Contents

Site Table of Contents

Previous Page

Next Page

Citations